CNBX Pharmaceuticals Inc.: Business Overview, Financials & Competitive Analysis
CNBX Pharmaceuticals Inc. scores 2/10 on the AskCyborg Cyborg Score (Challenged). Undercapitalized clinical-stage cannabinoid oncology company with minimal cash runway and no approved products, representing high-risk speculative opportunity dependent on successful capital raise and clinical validation. As of May 2024, the company had $73,406 in cash against expectations of minimum $1,000,000 in expenses during the next twelve months. The company.
What is CNBX Pharmaceuticals Inc.'s industry? CNBX Pharmaceuticals Inc. (cnbxpharma.com) operates in Oncology Drugs. AskCyborg classifies CNBX Pharmaceuticals Inc. under Oncology Drugs in its company registry.
CNBX Pharmaceuticals Inc. is a clinical stage company dedicated to discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. The company ...
Cyborg Score thesis
Undercapitalized clinical-stage cannabinoid oncology company with minimal cash runway and no approved products, representing...
Read the full analyst-debate transcript →Get the Latest CNBX Pharmaceuticals Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCNBX Pharmaceuticals Inc. Overview
Pro stress-test →CNBX Pharmaceuticals Inc. is a clinical stage company dedicated to discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. The company specializes in research and development of proprietary formulations aimed at treating various types of cancer, including colorectal cancer, melanoma, breast cancer, and prostate cancer, utilizing high throughput screening technology and advanced bioinformatics.
Strategic Profile
Pro stress-test →The company's lead product candidate is Cannabics SR, an oral capsule for advanced cancer and cancer anorexia cachexia syndrome (CACS), with RCC-33 as the leading anti-neoplastic drug candidate under development for colorectal cancer. R&D is conducted in a government-licensed lab facility in Israel with focus on development of cannabinoid-based therapies, medications and administration routes for cancer treatment.
Competitive Landscape
Pro stress-test →CNBX competes in the niche cannabinoid-based oncology segment against specialized pharmaceutical and biotechnology firms developing cannabinoid therapeutics for cancer. Competition includes companies pursuing cannabis-derived drug candidates, though CNBX's specific focus on formulated cannabinoids for gastrointestinal and dermatological cancers remains relatively specialized. The broader oncology therapeutics market includes major pharmaceutical companies and numerous biotech firms.
Industry Context
CNBX Pharmaceuticals Inc. operates in Oncology Drugs.
Key facts
Founded: 2004 · Headquarters: Bethesda, Maryland, United States · Employees: 1 · Revenue: Estimated $0.13M-$0.41M annually (based on FY2024 laboratory services revenue of $130,074)